Zabadinostat

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameZabadinostat
Drug Alias NamezabinostatAZD-9468AZD 9468CXD-101CXD101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsColorectal NeoplasmsLymphoma, T-Cell, PeripheralNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesIngenOx Therapeutics LtdNuance Biotech LtdGuangzhou Yourui Bioscience Co Ltd
Inactive CompaniesNational Institute For Health Research, United KingdomCelleron Therapeutics LtdUniversity Of Oxford
Active IndicationsLymphoma, T-Cell, Peripheral
Inactive IndicationsColorectal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank